ABSTRACT The management of prostate cancer relies on accurate staging. Prostate specific membrane antigen (PSMA) is a transmembrane glycoprotein highly expressed in prostate tissues, particularly prostate cancer. PSMA positron emission tomography (PSMA‐PET) is an emerging imaging modality that has recently established roles in prostate cancer imaging. In this narrative review, we aim to provide a concise overview of PSMA‐PET imaging including underlying principles, current roles in prostate cancer imaging and supporting evidence, and potential future directions. Conventional prostate cancer staging relied on a combination of CT and a whole body bone scan (WBBS). In existing studies, PSMA‐PET demonstrates superiority over conventional staging for prostate cancer in initial staging, as well as in re‐staging after biochemical recurrence. Currently, applications of PSMA and PSMA‐PET beyond prostate cancer imaging, such as in theranostics, and imaging of non‐prostatic diseases are being explored.
Ananthapadmanabhan et al. (Tue,) studied this question.